The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication suggests to deliver notable improvements in fat loss compared to current therapies. Initial research data have demonstrated substantial reductions in weight , possibly sig